Retinitis Pigmentosa Facebook Page

November 15, 2011

Retinitis Pigmentosa Awareness Page

http://www.facebook.com/pages/Retinitis-Pigmentosa-Awareness-Page/303807802963828

 

 

 

 

Advertisements

Study Shows Zeaxanthin Improves Vision in Elderly

November 15, 2011

The Zeaxanthin (zee-uh-zan-thin) and Visual Function Study (ZVF), conducted by eye nutrition pioneer Stuart Richer, PhD, OD at the Veterans Administration Hospital in Chicago, shows scientific evidence that dietary Zeaxanthin improved vision in night driving and fine detail, among others.
The ZVF Study followed 60 elderly veterans with early Age-Related Macular Degeneration (AMD) over a 12-month period that consumed 8 mg of dietary Zeaxanthin daily, showed improvement in the ability to drive at night, recognition of fine detail – an average improvement of 1.5 lines or 8.5 letters on an eye chart, and the disappearance of blind spots.

Read more: http://www.sacbee.com/2011/11/10/4044530/study-shows-zeaxanthin-improves.html#ixzz1dn2MQYyF


Stem Cell Therapy for Retinitis Pigmentosa

November 8, 2011

A young Romanian woman named Lydia was disappointed when conventional medicine gave her no hope in treatment of her retinitis pigmentosa. However, Dr. Omar Gonzalez of the Integra Medical Center, located in Mexico, has offered her hope as well as hope for other individuals diagnosed with vision problems including diabetic retinopathy and macular degeneration.

Dr. Omar Gonzalez has devised a stem cell treatment offering an alternative to conventional treatments for the disease. Dr. Gonzalez has designed a proprietary method that involves injection of stem cells behind the eye. Through such procedures, nearly 80% of individuals experienced slowing of the disease process, and approximately 60% have noticed an increase in their peripheral vision. None of the patients treated for retinitis pigmentosa at Integra Medical Center experienced post-treatment side effects, and defined any discomfort to merely “minimal” for up to 12 hours following the injection.

Within 30 minutes following the treatment, Lydia, who previously could hardly see four feet in front of her, could define shapes, people and even the color of their clothing. Lydia finally feels that she has some hope, not only to see her family members, but also to become more self-sufficient and less reliant on others to do things for her.

For more info:

http://www.placidway.com/article/717/Stem_Cell_Therapy_for_Retinitis_Pigmentosa

 


Macular Degeneration: Hot Topics in Treatment

November 7, 2011

Watch this video on AMD from

American Academy of Ophthalmology 2011

by Diana Do, MD; Julia A. Haller, MD

To watch video,  http://www.medscape.com/viewarticle/752736

 

 


Vascular Treatment to Prevent Progression of Dry AMD

November 7, 2011

The progressive disease occurs in the dry or early (non-exudative) form and the wet or late (exudative) form. Approximately 30 million people have AMD; 90% of those afflicted have the dry form, for which there is no approved treatment.

Dr. George Chiou determined the way to prevent the progression of dry AMD to wet AMD was to develop formulations that could restore choroidal blood flow, thus returning the natural process of nutrient and waste exchange and stabilization of the Bruch’s Membrane.

MacuCLEAR, Inc. (Plano, Texas) completed a Phase 1b/POC study of a topical agent, MC 1101, that significantly improved choroidal blood flow in eyes affected by AMD.

For more info:
http://www.dddmag.com/article-Vascular-Treatment-to-Prevent-Progression-of-Dry-AMD-11411.aspx


Gene Therapy Trial for Usher’s Syndrome To Begin

November 1, 2011

Oxford BioMedica announced that it had gained approval from the FDA to begin a Phase I/IIa Clinical Trial for a form of Usher’s Syndrome, Type 1B, which leads to progressive retinitis pigmentosa combined with a congenital hearing defect.

Usher syndrome is the most common form of deaf-blindness which affects approximately 30,000-50,000 patients in the US and Europe. One of the most common subtypes is Usher syndrome type 1B. The disease is caused by a mutation of the gene encoding myosin VIIA (MY07A).

The open label, dose escalation Phase I/IIa study will enrol up to 18 patients with Usher syndrome type 1B at the Oregon Health and Science University’s Casey Eye Institute, Portland, Oregon. The study, led by Professor Richard Weleber, will evaluate three dose levels for safety, tolerability and aspects of biological activity and is expected to be initiated by the end of 2011.

For more info:

http://irvaronsjournal.blogspot.com/2011/10/gene-therapy-update-1-first-clinical.html

http://eyedocnews.com/006188-gene-therapy-trial-for-retinitis-pigmentosa-based-on-usher%E2%80%99s-syndrome-to-begin/